| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00702-006-0442-5 |
| P698 | PubMed publication ID | 16604302 |
| P2093 | author name string | T Müller | |
| D Woitalla | |||
| O Goetze | |||
| H Przuntek | |||
| C Erdmann | |||
| S Muhlack | |||
| D Bremen | |||
| P2860 | cites work | Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases | Q29614910 |
| Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. | Q34124172 | ||
| Levodopa and the progression of Parkinson's disease | Q34553278 | ||
| The role of COMT inhibition in the treatment of Parkinson's disease | Q35626720 | ||
| Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic | Q40537501 | ||
| Gastric emptying in healthy volunteers after multiple doses of levodopa | Q42031336 | ||
| Tolcapone increases maximum concentration of levodopa | Q43503007 | ||
| Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase | Q44307365 | ||
| Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure | Q44423669 | ||
| Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease | Q44925879 | ||
| Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease | Q45101491 | ||
| An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off | Q45122889 | ||
| Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program | Q47321881 | ||
| Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association | Q48732841 | ||
| Levodopa in Parkinsonism: Potentiation of Central Effects with a Peripheral Inhibitor | Q51107835 | ||
| Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient | Q64784973 | ||
| Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease | Q64877938 | ||
| Effects of Chronic Levodopa Therapy on Dopa Pharmacokinetics | Q67218624 | ||
| Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone | Q67963198 | ||
| Catechol-O-methyltransferase activity in human and rat small intestine | Q68419621 | ||
| Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility | Q70379616 | ||
| Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients | Q72728432 | ||
| P433 | issue | 10 | |
| P921 | main subject | levodopa | Q300989 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 1441-1448 | |
| P577 | publication date | 2006-04-11 | |
| P1433 | published in | Journal of Neural Transmission | Q15750921 |
| P1476 | title | Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease | |
| P478 | volume | 113 |
| Q64760953 | Q64760953 |
| Q64761368 | Q64761368 |
| Q38740274 | A review of current and novel levodopa formulations for the treatment of Parkinson's disease |
| Q48337118 | Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats |
| Q36391866 | Betaine protects cerebellum from oxidative stress following levodopa and benserazide administration in rats |
| Q80469246 | Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease |
| Q46116294 | Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily |
| Q38140018 | Current status of safinamide for the drug portfolio of Parkinson's disease therapy |
| Q42642944 | Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study. |
| Q38064971 | Drug therapy in patients with Parkinson's disease |
| Q34109657 | Effects of dietary factors on levodopa pharmacokinetics. |
| Q83498343 | Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel |
| Q87764231 | Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition |
| Q42882771 | Fluctuation in plasma entacapone concentrations in accordance with variable plasma levodopa concentrations |
| Q46119482 | Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off. |
| Q52895921 | Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. |
| Q52855994 | Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease. |
| Q34593590 | Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort |
| Q42642958 | Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference |
| Q35223930 | Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. |
| Q100946083 | Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism |
| Q38103966 | Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations |
| Q84959462 | The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations |